Propagermanium monotherapy in patients with relapsed or refractory cancer.

Propagermanium monotherapy in patients with relapsed or refractory cancer. - PG monotherapy in cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030948

Enrollment

Registered

2022-03-31

Start date

2017-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory cancer.

Interventions

Propagerumanium 30mg day, consecutively for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: relapse or refractory cancer patients

Exclusion criteria

Exclusion criteria: 1) active lesion of the other type of cancer, except of gastric and head/neck cancer 2) Immunotherapy

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Adverse effect, Disease control ratio, Progression free survival, Predictive biomarker	—

Countries

Japan

Contacts

Public ContactShojiro Kikuchi

Hyogo College of Medicine Institute for Advanced Medical Sciences

skikuchi@hyo-med.ac.jp0798-45-6229

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026